Shanghai-based Convalife Pharmaceuticals has entered into a strategic partnership with fellow Chinese firm Jointown Pharmaceutical Group Co., Ltd (SHA: 600998) to collaborate on new drug development and the global research, development, and commercialization of related products. The partnership aims to leverage the strengths of both companies to advance innovative cancer therapies. Financial details of the agreement were not disclosed.
Convalife’s Pipeline and Jointown’s Capabilities
Convalife’s product pipeline includes a range of promising oncology candidates targeting various cancers, such as breast, lung, bile duct, prostate, pancreatic, and gastric cancers, as well as other solid and blood tumors. Key assets in its portfolio include CVL218, a second-generation PARP inhibitor; CVL237, the world’s only PI3Kβ/δ inhibitor; and a novel bispecific antibody for cancer indications. Jointown, as the largest private pharmaceutical enterprise in China, brings extensive resources and distribution capabilities to the partnership, with 31 provincial and 110 city logistics centers and over 400 subsidiaries.
Global Collaboration and Strategic Objectives
The partnership between Convalife and Jointown is designed to accelerate the development and commercialization of innovative cancer therapies on a global scale. By combining Convalife’s cutting-edge research and development capabilities with Jointown’s extensive market reach and logistics infrastructure, the collaboration aims to bring new treatments to patients more efficiently and effectively.-Fineline Info & Tech
